• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Inhibiton Therapeutics Files 8-K Update on Research Activities

Posted on: Thursday, 26 April 2007, 12:12 CDT

Inhibiton Therapeutics, Inc. (OTCBB: IHBT) announced today that it has filed a Current Report on Form 8-K (the "8-K Report") that provides an update on its research activities. The 8-K Report is based on an update from the primary researcher, Dr. Mildred Acevedo-Duncan, Ph.D., as to the progress of the research project the Company has been funding since September 2004 at the James A. Haley Veterans' Hospital in Tampa, Florida.

The Company has learned that approximately 100,000 compounds from the National Institutes of Health were screened for the PKC isozyme being studied. PKC isozymes control cell multiplication, and therefore, it is believed that a PKC inhibitor should block the proliferation of cancer cells. The research project is studying the theory that synthesis of a PKC inhibitor has the potential to block the proliferation of tumors and cancer cells. The researchers believe that synthesis of the PKC inhibitor holds potential for a cancer chemotherapeutic drug because the PKC isozyme is overproduced in benign tumors and malignant cancer cells but not in normal cells. Twenty compounds were identified that could serve as a PKC inhibitor and out of those twenty, one PKC inhibitor was chosen to be synthesized because it is closely related to current FDA approved therapies. This has been named as ICA-1. It is intended for cell culture testing to begin in April 2007 followed by nude mice studies and if appropriate, potentially clinical trials. Progress has also been made in the molecular biology to obtain the structure of the PKC isozyme in an attempt to verify that the PKC inhibitor works as intended.

Inhibiton Therapeutics, Inc. is a nominally capitalized development stage company focused on biotechnology research, development and potential commercialization of technologies and products for new cancer therapeutic agents and cancer fighting drugs called targeted therapies. The initial focus of the company's research is a protocol to investigate the effect of PKC isozymes on the regulation of brain cancer cells, which Inhibiton has been funding since September 2004.

The statements included in this press release concerning predictions of economic performance and management's plans and objectives constitute forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Any statement containing words such as "believes""anticipates""plans" or "expects" and other statements which are not historical facts contained in this release are forward-looking, and these statements involve risks and uncertainties and are based on current expectations. Consequently, actual results could differ materially from the expectations expressed in these forward-looking statements. Reference is made to the Company's filings with the Securities and Exchange Commission for a more complete discussion of such risks and uncertainties.

Source: Business Wire

More News in this Category